Stayble Therapeutics presents at Financial Stockholm's investor meeting on September 25, 2023

Stayble Therapeutics AB ("Stayble" or "the Company") announces today that the Company will participate in the investor meeting "Investera som proffsen," organized by Financial Stockholm on September 25, 2023.

On Monday, September 25, Stayble will be one of several companies presenting at Financial Stockholm's investor meeting at Scandic Anglais in Stockholm. At 17:50, Stayble's CEO, Andreas Gerward, will share insights about the Company's latest progress, future plans, and how Stayble is working to develop a treatment for degenerative disc disease and chronic disc herniation.

To get more information about the event and Stayble's presentation, visit this link to read more and register for the event: https://financialstockholm.com/inbjudan-investera-som-proffsen-med-anders-strom-en-guide-till-ekonomiskt-oberoende-hotell-anglais-stureplan-25-september/

After the event, the presentation will be available on Stayble's website.

For more information

Andreas Gerward, CEO Stayble Therapeutics AB

Mail: andreas.gerward@stayble.se

Phone: +46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical-stage pharmaceutical company developing the STA363 injection treatment for degenerative disc disease (DDD) and chronic disc herniation (LDH). Stayble's vision is to offer patients a simple and effective treatment that addresses the underlying cause of the patient's chronic pain and provides lasting pain relief and increased physical function. Aimed at patients who are not helped by physiotherapy and painkillers, the treatment is a single injection that is expected to last a lifetime and requires minimal rehabilitation. The company is now focused on clinical development and is currently conducting a Phase 2b clinical trial in DDD and a Phase Ib trial in LDH.

Svensk Kapitalmarknadsgranskning AB is the Company’s Certified Adviser.